Superluminal Medicines

Superluminal Medicines

https://www.superluminalrx.com/

Superluminal Medicines is a US drug discovery company with an AI based GPCR discovery platform. Its lead program, a selective MC4R agonist for rare genetic and hypothalamic obesity, is set for a Phase 1 trial by end of 2026 after a $60 million Series B led by BVF Partners in September 2026.

Superluminal Medicines Raises $60 Million for Obesity Drug Trial

September 03, 2026

The Series B financing will support a Phase 1 trial of a treatment for rare genetic forms of obesity by the end of 2026.
Free newsletter

Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates